Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 2, 2011, Pages 387-394

  Reijm, E A ^a   Jansen, M P H M ^a   Ruigrok Ritstier, K ^a   Van Staveren, I L ^a   Look, M P ^a   Van Gelder, M E Meijer ^a   Sieuwerts, A M ^a   Sleijfer, S ^a   Foekens, J A ^a   Berns, E M J J ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Advanced disease; ESR1; EZH2; siRNAs; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR ALPHA; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; TAMOXIFEN; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UPREGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; HUMANS; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; POLYUNSATURATED ALKAMIDES; PROGNOSIS; RNA, MESSENGER; RNA, SMALL INTERFERING; TAMOXIFEN; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 78650987804     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0836-9     Document Type: Article

References (23)

1. MP Jansen JA Foekens IL van Staveren, et al. 2005 Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling J Clin Oncol 23 732 740 1:CAS:528:DC%2BD2MXitVKitr4%3D 10.1200/JCO.2005.05.145 15681518 (Pubitemid 46224172)
2. B Schuettengruber D Chourrout M Vervoort, et al. 2007 Genome regulation by polycomb and trithorax proteins Cell 128 735 745 1:CAS:528: DC%2BD2sXis12isr8%3D 10.1016/j.cell.2007.02.009 17320510 (Pubitemid 46273581)
3. R Cao L Wang H Wang, et al. 2002 Role of histone H3 lysine 27 methylation in Polycomb-group silencing Science 298 1039 1043 1:CAS:528: DC%2BD38Xot12rs7g%3D 10.1126/science.1076997 12351676 (Pubitemid 35247314)
4. B Czermin R Melfi D McCabe, et al. 2002 Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites Cell 111 185 196 1:CAS:528:DC%2BD38Xotlahsr8%3D 10.1016/S0092-8674(02)00975-3 12408863 (Pubitemid 35292439)
5. A Kuzmichev K Nishioka H Erdjument-Bromage, et al. 2002 Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein Genes Dev 16 2893 2905 1:CAS:528:DC%2BD38XovVejsLY%3D 10.1101/gad.1035902 12435631 (Pubitemid 35334738)
6. R Margueron G Li K Sarma, et al. 2008 Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms Mol Cell 32 503 518 1:CAS:528: DC%2BD1cXhsVKgt7fP 10.1016/j.molcel.2008.11.004 19026781
7. M Jansen J Foekens K Ritstier, et al. 2005 A miniPathway for tamoxifen therapy resistance Breast Cancer Res Treat 94 S31
8. K Collett GE Eide J Arnes, et al. 2006 Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer Clin Cancer Res 12 1168 1174 1:CAS:528:DC%2BD28XhsFalt7c%3D 10.1158/1078-0432.CCR-05-1533 16489070 (Pubitemid 43342505)
9. IM Bachmann OJ Halvorsen K Collett, et al. 2006 EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast J Clin Oncol 24 268 273 1:CAS:528:DC%2BD28XhtVKqtrg%3D 10.1200/JCO.2005.01.5180 16330673 (Pubitemid 46622055)
10. JD Raman NP Mongan SK Tickoo, et al. 2005 Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder Clin Cancer Res 11 8570 8576 1:CAS:528:DC%2BD2MXhtlWrsb7N 10.1158/1078-0432.CCR-05- 1047 16361539 (Pubitemid 43005902)
11. CG Kleer Q Cao S Varambally, et al. 2003 EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells Proc Natl Acad Sci USA 100 11606 11611 1:CAS:528:DC%2BD3sXotFKmt7g%3D 10.1073/pnas.1933744100 14500907 (Pubitemid 37205983)
12. S Varambally SM Dhanasekaran M Zhou, et al. 2002 The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 624 629 1:CAS:528:DC%2BD38Xns1Ontrk%3D 10.1038/nature01075 12374981
13. LM McShane DG Altman W Sauerbrei, et al. 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
14. JL Hayward PP Carbone JC Heuson, et al. 1977 Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer 39 1289 1294 1:STN:280:DyaE1c%2Fit1eksg%3D%3D 10.1002/1097-0142(197703)39: 3<1289::AID-CNCR2820390340>3.0.CO;2-F 912660
15. JA Foekens H Portengen WL van Putten, et al. 1989 Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols Cancer Res 49 5823 5828 1:CAS:528:DyaK3cXhvFCmsQ%3D%3D 2676151
16. AM Sieuwerts ME Meijer-van Gelder M Timmermans, et al. 2005 How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study Clin Cancer Res 11 7311 7321 1:CAS:528:DC%2BD2MXhtFartb3F 10.1158/1078-0432.CCR-05- 0560 16243802 (Pubitemid 41507689)
17. MP Jansen K Ruigrok-Ritstier LC Dorssers, et al. 2009 Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer Breast Cancer Res Treat 116 263 271 1:CAS:528:DC%2BD1MXntF2nt7o%3D 10.1007/s10549-008-0125-z 18629630
18. T van Agthoven AM Sieuwerts J Veldscholte, et al. 2009 CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer Br J Cancer 101 1824 1832 10.1038/sj.bjc.6605423 19904269
19. LJ van 't Veer H Dai MJ van de Vijver, et al. 2002 Gene expression profiling predicts clinical outcome of breast cancer Nature 415 530 536 10.1038/415530a 11823860 (Pubitemid 34130608)
20. J Yu Q Cao R Mehra, et al. 2007 Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer Cancer Cell 12 419 431 1:CAS:528:DC%2BD2sXhtl2nur3F 10.1016/j.ccr.2007.10.016 17996646 (Pubitemid 350046407)
21. S Varambally Q Cao RS Mani, et al. 2008 Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Science 322 1695 1699 1:CAS:528:DC%2BD1cXhsVOgtbvO 10.1126/science.1165395 19008416
22. CF Wong RL Tellam 2008 MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis J Biol Chem 283 9836 9843 1:CAS:528:DC%2BD1cXkt1aktrw%3D 10.1074/jbc.M709614200 18281287
23. J Kota RR Chivukula KA O'Donnell, et al. 2009 Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model Cell 137 1005 1017 1:CAS:528:DC%2BD1MXps1eiurg%3D 10.1016/j.cell.2009.04.021 19524505